Trump announces trade deal with EU following months of negotiations
Troy Wichterman, Chief Financial Officer of BioLife Solutions Inc. (NASDAQ:BLFS), recently sold 159 shares of the company's common stock, according to a recent SEC filing. The company, which currently maintains a market capitalization of $1.29 billion, has seen its stock surge approximately 56% over the past year according to InvestingPro data. The shares were sold at a price of $26.54 each, totaling approximately $4,219. Following this transaction, Wichterman holds 121,620 shares directly. The sale was executed as part of a Rule 10b5-1 trading plan, which was adopted to satisfy tax withholding obligations related to the vesting of restricted stock. According to InvestingPro analysis, the stock is currently trading near its 52-week high of $29.55, with a "GOOD" overall Financial Health score. For deeper insights into insider trading patterns and 12 additional ProTips, subscribers can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, BioLife Solutions has been the focus of several analyst reports. Maxim Group raised its price target for BioLife Solutions to $34, anticipating a return to durable top-line growth in 2025 due to the company's strategic shift towards its Cell and Gene Therapy tools. KeyBanc Capital Markets maintained its Overweight rating and a $33.00 price target, citing the recent appointment of Tony Hunt to the Board of Directors and a strong financial position following the sale of CBS and SciSafe.
Benchmark maintained its Buy rating with a steady price target of $30.00, after the company sold its SciSafe biostorage service division, which is expected to enhance gross margins and cut overhead costs. KeyBanc Capital Markets increased its price target to $33, highlighting the successful execution of three asset sales under the new CEO's leadership.
However, H.C. Wainwright adjusted the price target for BioLife Solutions to $27 from the previous $29 after the company completed the sale of its last wholly owned freezer subsidiary, Arctic Solutions, and its wholly owned biostorage subsidiary, SciSafe Holdings. These developments are part of BioLife's strategic shift to focus on its proprietary cell processing products. Despite the lowered revenue projections and price target adjustment, all firms reaffirm their confidence in the stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.